Corbus Pharmaceuticals Holdings Inc.
Rank 17
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
$7.1300
USD
1.85%
Market cap
$460,965,858
Total volume
$5,560,180
Shares outstanding
64,651,593
Rank 17
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
Markets
| Exchange | Symbol | Volume (24h) | Volume (%) | Price |
|---|---|---|---|---|
|
|
CRBP |
$5,560,180
|
100% |
$7.1300
|
Chart